| 11001 | Primary biliary cholangitis | GCST003129 | 9.82e-05 |
| 11002 | Average diameter for VLDL particles | GCST90093002 | 9.81e-05 |
| 11003 | SLAMF1 levels | GCST90274835 | 9.81e-05 |
| 11004 | Psoriasis | GCST90468147 | 9.79e-05 |
| 11005 | ASGR1 levels | GCST90468375 | 9.76e-05 |
| 11006 | ICAM3/NOTCH1 ratio | GCST90315122 | 9.75e-05 |
| 11007 | CRYBB1 levels | GCST90468874 | 9.72e-05 |
| 11008 | Arthropathies in other diseases classified elsewhere | FING00000108 | 9.71e-05 |
| 11009 | Linoleic acid levels | GCST90502012 | 9.67e-05 |
| 11010 | Cholesteryl Esters in Medium LDL | GCST90498738 | 9.64e-05 |
| 11011 | CD48/CRTAM ratio | GCST90313839 | 9.64e-05 |
| 11012 | Phospholipids in large LDL | GCST90498049 | 9.59e-05 |
| 11013 | Burger liking | GCST90094715 | 9.59e-05 |
| 11014 | IDP T1 FAST ROIs R postcent gyrus | GCST90002484 | 9.53e-05 |
| 11015 | Triglyceride to HDL cholesterol ratio | GCST90295953 | 9.52e-05 |
| 11016 | CD40/TNFRSF14 ratio | GCST90313830 | 9.49e-05 |
| 11017 | Body-mass index, inverse-rank normalized | FING00000222 | 9.44e-05 |
| 11018 | Fasting plasma glucose | GCST90297787 | 9.44e-05 |
| 11019 | PLXNA4/USP8 ratio | GCST90315690 | 9.36e-05 |
| 11020 | PALM3 levels | GCST90470153 | 9.31e-05 |
| 11021 | Cholesterol levels in very large VLDL | GCST90500517 | 9.26e-05 |
| 11022 | Triglycerides to total lipids in very large HDL percentage (UKB data field 23633) | GCST90269730 | 9.23e-05 |
| 11023 | SIGLEC1/SSC5D ratio | GCST90315844 | 9.21e-05 |
| 11024 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502555 | 9.19e-05 |
| 11025 | Takes medication for high cholesterol? | GCST90475208 | 9.18e-05 |
| 11026 | Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144) | GCST90132931 | 9.18e-05 |
| 11027 | Kela-code for severe mental illness | FING00000707 | 9.17e-05 |
| 11028 | CD74/JAM2 ratio | GCST90313893 | 9.07e-05 |
| 11029 | SKAP1 levels | GCST90470645 | 9.06e-05 |
| 11030 | Mineral and other dietary supplements - None of the above | Medication | UKBB00000474 | 9.06e-05 |
| 11031 | Triglycerides to Total Lipids in IDL percentage | GCST90497676 | 9.04e-05 |
| 11032 | rfMRI connectivity (ICA25 edge 101) | GCST90004744 | 9.03e-05 |
| 11033 | Hypothyroidism (PheCode 244) | GCST90475647 | 9.02e-05 |
| 11034 | Total lipids in very large HDL | GCST90500423 | 9.01e-05 |
| 11035 | GDF15 levels | GCST90469321 | 8.98e-05 |
| 11036 | Total lipids in medium VLDL | GCST90498994 | 8.95e-05 |
| 11037 | Concentration of IDL particles | GCST90497606 | 8.95e-05 |
| 11038 | ITGB5/SIAE ratio | GCST90315234 | 8.90e-05 |
| 11039 | IGF2R levels | GCST90469526 | 8.89e-05 |
| 11040 | ECHS1 levels | GCST90469063 | 8.89e-05 |
| 11041 | Triglycerides in medium LDL | GCST90498870 | 8.87e-05 |
| 11042 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 8.86e-05 |
| 11043 | APP levels | GCST90468344 | 8.81e-05 |
| 11044 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502633 | 8.79e-05 |
| 11045 | CDC37/SNAP29 ratio | GCST90313935 | 8.75e-05 |
| 11046 | Cholesteryl ester levels in very small VLDL | GCST90093030 | 8.72e-05 |
| 11047 | CPB1/PRSS2 ratio | GCST90314211 | 8.70e-05 |
| 11048 | Cholesteryl esters to total lipids ratio in medium LDL | GCST90092907 | 8.67e-05 |
| 11049 | BAX/MAX ratio | GCST90313466 | 8.65e-05 |
| 11050 | ARHGEF12/IRAK4 ratio | GCST90313350 | 8.64e-05 |
| 11051 | Triglycerides in HDL | GCST90497467 | 8.61e-05 |
| 11052 | SCARF1 levels | GCST90470536 | 8.60e-05 |
| 11053 | aseg rh number HolesBeforeFixing | GCST90002647 | 8.59e-05 |
| 11054 | TYRP1 levels | GCST90470998 | 8.57e-05 |
| 11055 | Phospholipids in small LDL | GCST90499681 | 8.56e-05 |
| 11056 | Omega-3 fatty acid levels | GCST90502424 | 8.54e-05 |
| 11057 | Triglycerides to total lipids ratio in large LDL | GCST90092867 | 8.52e-05 |
| 11058 | Cholesterol, total | GCST002221 | 8.49e-05 |
| 11059 | Pregnenediol sulfate (C21H34O5S) levels | GCST90199861 | 8.48e-05 |
| 11060 | HYOU1/RARRES2 ratio | GCST90315103 | 8.43e-05 |
| 11061 | WFIKKN2 levels | GCST90471077 | 8.43e-05 |
| 11062 | Miserableness | Mental health | UKBB00000478 | 8.42e-05 |
| 11063 | NOTCH1/SEMA7A ratio | GCST90315545 | 8.42e-05 |
| 11064 | CPA1/CTRB1 ratio | GCST90314203 | 8.38e-05 |
| 11065 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 8.36e-05 |
| 11066 | Pain in limb | FING00001138 | 8.35e-05 |
| 11067 | TFF2 levels | GCST90470836 | 8.34e-05 |
| 11068 | Phospholipid levels in small VLDL | GCST90092976 | 8.33e-05 |
| 11069 | PGLYRP1 levels | GCST90470219 | 8.31e-05 |
| 11070 | GLB1/GUSB ratio | GCST90314931 | 8.29e-05 |
| 11071 | NUDT5/RWDD1 ratio | GCST90315580 | 8.28e-05 |
| 11072 | DSG3 levels | GCST90469043 | 8.27e-05 |
| 11073 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 8.25e-05 |
| 11074 | Prostate cancer | GCST006085 | 8.25e-05 |
| 11075 | Hyperparathyroidism (PheCode 252.1) | GCST90475693 | 8.23e-05 |
| 11076 | FGFBP1 levels | GCST90469230 | 8.22e-05 |
| 11077 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 8.20e-05 |
| 11078 | Phospholipids in medium LDL | GCST90498831 | 8.16e-05 |
| 11079 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 8.16e-05 |
| 11080 | Cancer | GCST90086052 | 8.15e-05 |
| 11081 | Asthma-related pneumonia | FING00000119 | 8.15e-05 |
| 11082 | Autoimmune hyperthyroidism | FING00000134 | 8.14e-05 |
| 11083 | Scar conditions and fibrosis of skin (PheCode 701.2) | GCST90476198 | 8.10e-05 |
| 11084 | Abnormal results of function study of liver (PheCode 573.7) | GCST90476097 | 8.09e-05 |
| 11085 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500333 | 8.06e-05 |
| 11086 | FKBP4/RWDD1 ratio | GCST90314840 | 8.05e-05 |
| 11087 | Percentage of trisyalated structures in total plasma glycans (GP97) | GCST90668541 | 8.05e-05 |
| 11088 | MMP9/OSM ratio | GCST90315468 | 8.05e-05 |
| 11089 | CDCP1 levels | GCST90468667 | 8.04e-05 |
| 11090 | KLK10 levels | GCST90469696 | 8.03e-05 |
| 11091 | Free cholesterol to total lipids in small LDL percentage (UKB data field 23627) | GCST90269724 | 8.02e-05 |
| 11092 | Skin cancer | GCST90475189 | 7.99e-05 |
| 11093 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 7.93e-05 |
| 11094 | COPD/asthma/ILD related infections | FING00000353 | 7.92e-05 |
| 11095 | Omega-6 fatty acid levels | GCST90502101 | 7.90e-05 |
| 11096 | Basophil count | GCST90002293 | 7.89e-05 |
| 11097 | HAVCR2/TNFRSF1B ratio | GCST90315030 | 7.89e-05 |
| 11098 | Eosinophill count | Blood count | UKBB00000206 | 7.89e-05 |
| 11099 | GLB1 levels | GCST90469355 | 7.85e-05 |
| 11100 | Triglycerides to total lipids ratio in small HDL | GCST90092955 | 7.81e-05 |
| 11101 | Cholesterol to total lipids ratio in very small VLDL | GCST90093029 | 7.80e-05 |
| 11102 | RETN/RNASET2 ratio | GCST90315768 | 7.79e-05 |
| 11103 | HGFAC levels | GCST90469448 | 7.79e-05 |
| 11104 | Number of sexual partners in opposite-sex sexual behavior | GCST90026481 | 7.78e-05 |
| 11105 | DNAJB1/PPME1 ratio | GCST90314510 | 7.74e-05 |
| 11106 | Androstenediol (3beta,17beta) disulfate (2) levels | GCST90199851 | 7.68e-05 |
| 11107 | F2R/TMSB10 ratio | GCST90314738 | 7.60e-05 |
| 11108 | B2M levels | GCST90468409 | 7.59e-05 |
| 11109 | DDC levels | GCST90468967 | 7.59e-05 |
| 11110 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 7.58e-05 |
| 11111 | Crohn's disease of large intestine | FING00000368 | 7.56e-05 |
| 11112 | SIGLEC10 levels | GCST90470630 | 7.55e-05 |
| 11113 | VWC2 levels | GCST90471064 | 7.54e-05 |
| 11114 | ANXA4/FADD ratio | GCST90313291 | 7.53e-05 |
| 11115 | Cholesteryl Esters to Total Lipids in Medium LDL percentage | GCST90498758 | 7.51e-05 |
| 11116 | MASP1 levels | GCST90469863 | 7.51e-05 |
| 11117 | Concentration of small LDL particles | GCST90092963 | 7.47e-05 |
| 11118 | FXN/TRIAP1 ratio | GCST90314899 | 7.45e-05 |
| 11119 | Cholesterol to total lipids ratio in very large VLDL | GCST90093017 | 7.43e-05 |
| 11120 | FAM3B/GUCA2A ratio | GCST90314779 | 7.43e-05 |
| 11121 | Whole body fat mass (UKB data field 23100) | GCST90428121 | 7.41e-05 |
| 11122 | Cholesteryl Esters in LDL | GCST90498374 | 7.41e-05 |
| 11123 | Principal component-derived dietary pattern 13 | GCST90133018 | 7.40e-05 |
| 11124 | Phospholipids in medium VLDL | GCST90499024 | 7.38e-05 |
| 11125 | Triglycerides in small LDL | GCST90499722 | 7.34e-05 |
| 11126 | Cholesterol in Small LDL | GCST90499555 | 7.34e-05 |
| 11127 | Participation in an health questionnaire (not invited vs invited) | GCST90012794 | 7.32e-05 |
| 11128 | Clinical LDL cholesterol levels | GCST90497219 | 7.30e-05 |
| 11129 | Total lipids in very large VLDL | GCST90500614 | 7.29e-05 |
| 11130 | Cholesteryl ester levels in large VLDL | GCST90092870 | 7.23e-05 |
| 11131 | Urine betaine levels in chronic kidney disease | GCST90264859 | 7.20e-05 |
| 11132 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 7.20e-05 |
| 11133 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502373 | 7.18e-05 |
| 11134 | Fluid intelligence score (baseline) | GCST90565842 | 7.18e-05 |
| 11135 | NRP2 levels | GCST90470086 | 7.16e-05 |
| 11136 | BTN2A1/SIGLEC1 ratio | GCST90313548 | 7.14e-05 |
| 11137 | Hyperlipidemia (PheCode 272.1) | GCST90475718 | 7.13e-05 |
| 11138 | Free cholesterol in large LDL | GCST90497987 | 7.12e-05 |
| 11139 | Phospholipids to Total Lipids in Medium VLDL percentage | GCST90499043 | 7.11e-05 |
| 11140 | Triglyceride levels in medium LDL | GCST90092914 | 7.05e-05 |
| 11141 | Free cholesterol in IDL | GCST90497561 | 7.05e-05 |
| 11142 | AKT1S1/FHIT ratio | GCST90313228 | 7.05e-05 |
| 11143 | KLRF1 levels | GCST90469712 | 7.03e-05 |
| 11144 | Triglycerides to total lipids in medium LDL percentage (UKB data field 23623) | GCST90269720 | 6.98e-05 |
| 11145 | CCL5 levels | GCST90468584 | 6.96e-05 |
| 11146 | ADGRE2/IFNGR1 ratio | GCST90313177 | 6.95e-05 |
| 11147 | Clonal haematopoiesis of indeterminate potential (DNMT3A mutation) | GCST90165271 | 6.94e-05 |
| 11148 | Total lipids in medium VLDL | GCST90499004 | 6.88e-05 |
| 11149 | CCL5/SELP ratio | GCST90313705 | 6.87e-05 |
| 11150 | Sodium (mean, inv-norm transformed) | GCST90476395 | 6.86e-05 |
| 11151 | Cholesteryl esters in very large VLDL | GCST90500556 | 6.78e-05 |
| 11152 | Phospholipids to Total Lipids in IDL percentage | GCST90497642 | 6.78e-05 |
| 11153 | Prostate cancer | GCST90428117 | 6.76e-05 |
| 11154 | Phospholipids in small LDL | GCST90499673 | 6.74e-05 |
| 11155 | METAP2/PFKFB2 ratio | GCST90315431 | 6.72e-05 |
| 11156 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502147 | 6.72e-05 |
| 11157 | Volume of right cortical nucleus | GCST90475033 | 6.71e-05 |
| 11158 | LDL cholesterol | GCST002222 | 6.70e-05 |
| 11159 | red cell diameter width (RDW, minimum, inv-norm transformed) | GCST90476365 | 6.69e-05 |
| 11160 | Phospholipid levels in very small VLDL | GCST90093036 | 6.68e-05 |
| 11161 | Ulcerative colitis (strict) with PSC | FING00001389 | 6.65e-05 |
| 11162 | VEGFB levels | GCST90471035 | 6.63e-05 |
| 11163 | NAGA levels | GCST90469994 | 6.63e-05 |
| 11164 | Triglycerides in small LDL (UKB data field 23550) | GCST90269647 | 6.61e-05 |
| 11165 | Systemic lupus erythematosus | GCST90011866 | 6.59e-05 |
| 11166 | LAG3 levels | GCST90469727 | 6.53e-05 |
| 11167 | CLEC1B/SORT1 ratio | GCST90314104 | 6.53e-05 |
| 11168 | Free cholesterol to total lipids ratio in large LDL | GCST90092861 | 6.52e-05 |
| 11169 | Cholesteryl esters to total lipids in small HDL percentage (UKB data field 23646) | GCST90269743 | 6.52e-05 |
| 11170 | FOLR2/THY1 ratio | GCST90314867 | 6.47e-05 |
| 11171 | Non-oily fish consumption | GCST90132994 | 6.47e-05 |
| 11172 | IL22 levels | GCST90469582 | 6.45e-05 |
| 11173 | Tryptophan betaine levels | GCST90199819 | 6.42e-05 |
| 11174 | Chronic nephritic syndrome | FING00000295 | 6.41e-05 |
| 11175 | Eosinophill count (UKB data field 30150) | GCST90468068 | 6.40e-05 |
| 11176 | OSM/TGFA ratio | GCST90315590 | 6.39e-05 |
| 11177 | DTI TBSS MD Posterior limb of internal capsule R | GCST90384590 | 6.36e-05 |
| 11178 | CCL24 levels | GCST90468576 | 6.33e-05 |
| 11179 | Cholesterol in Large VLDL | GCST90498123 | 6.30e-05 |
| 11180 | Aspartate aminotransferase levels (UKB data field 30650) | GCST90468063 | 6.27e-05 |
| 11181 | Rheumatoid arthritis | GCST90132224 | 6.25e-05 |
| 11182 | Total fatty acids levels (UKB data field 23442) | GCST90269539 | 6.24e-05 |
| 11183 | PIGR levels | GCST90470232 | 6.21e-05 |
| 11184 | Triglyceride levels in LDL | GCST90092890 | 6.21e-05 |
| 11185 | Polyunsaturated fatty acid levels | GCST90502140 | 6.21e-05 |
| 11186 | white blood cell count (WBC, maximum, inv-norm transformed) | GCST90476451 | 6.19e-05 |
| 11187 | CPB2 levels | GCST90468840 | 6.18e-05 |
| 11188 | TNFSF8 levels | GCST90470923 | 6.18e-05 |
| 11189 | Eosinophil percentage of white cells | GCST90002382 | 6.14e-05 |
| 11190 | L1CAM/SEZ6L ratio | GCST90315266 | 6.12e-05 |
| 11191 | BTC levels | GCST90468476 | 6.09e-05 |
| 11192 | Triglyceride levels in large VLDL | GCST90092878 | 6.05e-05 |
| 11193 | Disorders of lipid metabolism (PheCode 272) | GCST90475715 | 6.01e-05 |
| 11194 | EPHA4 levels | GCST90469131 | 6.00e-05 |
| 11195 | Concentration of medium VLDL particles | GCST90092923 | 5.96e-05 |
| 11196 | Apples liking | GCST90094691 | 5.94e-05 |
| 11197 | Triglycerides in small HDL (UKB data field 23578) | GCST90269675 | 5.94e-05 |
| 11198 | Polyunsaturated fatty acid levels | GCST90499266 | 5.94e-05 |
| 11199 | Linoleic acid to total fatty acids percentage | GCST90502321 | 5.91e-05 |
| 11200 | CRNN levels | GCST90468869 | 5.91e-05 |
| 11201 | Rheumatoid arthritis | FING00001267 | 5.91e-05 |
| 11202 | aparc-Desikan lh volume precuneus | GCST90002792 | 5.89e-05 |
| 11203 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500373 | 5.86e-05 |
| 11204 | PTP4A3 levels | GCST90470375 | 5.86e-05 |
| 11205 | C9 levels | GCST90468505 | 5.84e-05 |
| 11206 | Cholesteryl Esters to Total Lipids in IDL percentage | GCST90497549 | 5.84e-05 |
| 11207 | Mineral and other dietary supplements - Fish oil (including cod liver oil) | Medication | UKBB00000472 | 5.83e-05 |
| 11208 | Thyrotoxicosis with diffuse goitre | FING00001361 | 5.82e-05 |
| 11209 | APOB levels | UKBB00000041 | 5.82e-05 |
| 11210 | Hyperthyroidism | GCST90319319 | 5.80e-05 |
| 11211 | Cholesteryl esters to total lipids ratio in very large VLDL | GCST90093019 | 5.77e-05 |
| 11212 | LAYN/TNFRSF4 ratio | GCST90315291 | 5.77e-05 |
| 11213 | Cholesterol levels in very large VLDL | GCST90093016 | 5.74e-05 |
| 11214 | Phospholipids to total lipids ratio in large HDL | GCST90092853 | 5.74e-05 |
| 11215 | OBP2B levels | GCST90470113 | 5.70e-05 |
| 11216 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475454 | 5.69e-05 |
| 11217 | Triglycerides to Total Lipids in Very Small VLDL percentage | GCST90500886 | 5.69e-05 |
| 11218 | Polyunsaturated fatty acid levels | GCST90502618 | 5.68e-05 |
| 11219 | Physical activity | GCST90093324 | 5.67e-05 |
| 11220 | Glycine levels | GCST90497315 | 5.67e-05 |
| 11221 | MEP1B levels | GCST90469888 | 5.67e-05 |
| 11222 | Aniseed liking | GCST90094689 | 5.66e-05 |
| 11223 | Docosahexaenoic acid to total fatty acids percentage | GCST90497268 | 5.66e-05 |
| 11224 | Lymphocyte count | GCST90002316 | 5.66e-05 |
| 11225 | CALCOCO1/CASP3 ratio | GCST90313596 | 5.64e-05 |
| 11226 | Cholesteryl esters to total lipids ratio in large VLDL | GCST90092871 | 5.63e-05 |
| 11227 | Saturated fatty acids to total fatty acids percentage | GCST90502684 | 5.62e-05 |
| 11228 | Psoriasis (PheCode 696.4) | GCST90476187 | 5.62e-05 |
| 11229 | AmygNuclei rh volume Lateral-nucleus | GCST90002658 | 5.62e-05 |
| 11230 | Phospholipids in LDL | GCST90498432 | 5.61e-05 |
| 11231 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500949 | 5.60e-05 |
| 11232 | Cholesteryl esters in medium LDL (UKB data field 23541) | GCST90269638 | 5.56e-05 |
| 11233 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 5.56e-05 |
| 11234 | Educational attainment | GCST003496 | 5.55e-05 |
| 11235 | EFNA4/VWC2 ratio | GCST90314607 | 5.54e-05 |
| 11236 | Principal component-derived dietary pattern 29 | GCST90133034 | 5.54e-05 |
| 11237 | Monounsaturated fatty acid levels | GCST90499094 | 5.53e-05 |
| 11238 | CST5 levels | GCST90468895 | 5.51e-05 |
| 11239 | LBR/LGALS8 ratio | GCST90315294 | 5.51e-05 |
| 11240 | FRZB levels | GCST90469269 | 5.50e-05 |
| 11241 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498092 | 5.47e-05 |
| 11242 | S100A4/SNAP29 ratio | GCST90315801 | 5.47e-05 |
| 11243 | Prostate cancer | GCST90274714 | 5.44e-05 |
| 11244 | Triglyceride levels in very large VLDL | GCST90093026 | 5.44e-05 |
| 11245 | Eosinophil count | GCST004606 | 5.43e-05 |
| 11246 | FCRL6 levels | GCST90469209 | 5.40e-05 |
| 11247 | CD27/DLL1 ratio | GCST90313771 | 5.40e-05 |
| 11248 | Eosinophill percentage | Blood count | UKBB00000207 | 5.40e-05 |
| 11249 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90093046 | 5.38e-05 |
| 11250 | DTI autoptx FA ptr l tract | GCST90385131 | 5.38e-05 |
| 11251 | Cerebrospinal fluid beta-hydroxyisovaleroylcarnitine levels | GCST90318013 | 5.37e-05 |
| 11252 | GPRC5C levels | GCST90469398 | 5.36e-05 |
| 11253 | CRHBP levels | GCST90468860 | 5.32e-05 |
| 11254 | Eosinophil count | GCST90002381 | 5.31e-05 |
| 11255 | Lymphocyte count | Blood count | UKBB00000411 | 5.30e-05 |
| 11256 | Orotidine levels | GCST90200681 | 5.29e-05 |
| 11257 | Citrate levels | GCST90092813 | 5.29e-05 |
| 11258 | Phospholipids to total lipids in small LDL percentage (UKB data field 23624) | GCST90269721 | 5.27e-05 |
| 11259 | S100A11/S100A12 ratio | GCST90315798 | 5.26e-05 |
| 11260 | MRC1 levels | GCST90469939 | 5.25e-05 |
| 11261 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498682 | 5.21e-05 |
| 11262 | First line medication for Crohn's disease | FING00000544 | 5.21e-05 |
| 11263 | DTI TBSS L1 Anterior corona radiata R | GCST90384450 | 5.20e-05 |
| 11264 | TCL1A levels | GCST90470817 | 5.19e-05 |
| 11265 | MMP8/OLR1 ratio | GCST90315464 | 5.19e-05 |
| 11266 | Triglycerides in LDL | GCST90498469 | 5.18e-05 |
| 11267 | Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452) | GCST90269549 | 5.18e-05 |
| 11268 | Age at first birth | GCST90000048 | 5.17e-05 |
| 11269 | Triglycerides | GCST000758 | 5.16e-05 |
| 11270 | CD99L2/CPM ratio | GCST90313925 | 5.16e-05 |
| 11271 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) | GCST90092943 | 5.13e-05 |
| 11272 | Triglycerides to total lipids ratio in very large HDL | GCST90093015 | 5.12e-05 |
| 11273 | TST levels | GCST90470982 | 5.09e-05 |
| 11274 | Triglyceride to HDL cholesterol ratio | GCST90295950 | 5.09e-05 |
| 11275 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 5.08e-05 |
| 11276 | Alcohol liking | GCST90094688 | 5.07e-05 |
| 11277 | SIGLEC6 levels | GCST90470634 | 5.06e-05 |
| 11278 | ITGB2 levels | GCST90469644 | 5.06e-05 |
| 11279 | ATOX1/TMSB10 ratio | GCST90313377 | 5.02e-05 |
| 11280 | Linoleic acid levels | GCST90502010 | 5.01e-05 |
| 11281 | Eosinophil count | GCST90002299 | 5.01e-05 |
| 11282 | Total lipid levels in very large VLDL | GCST90093022 | 4.99e-05 |
| 11283 | OLFM4 levels | GCST90470121 | 4.99e-05 |
| 11284 | Triglyceride levels in large LDL | GCST90092866 | 4.99e-05 |
| 11285 | GP1BA/HBEGF ratio | GCST90314956 | 4.97e-05 |
| 11286 | GYS1/PPP1R2 ratio | GCST90315001 | 4.97e-05 |
| 11287 | Phospholipid levels in medium VLDL | GCST90092924 | 4.96e-05 |
| 11288 | EPHB6/VWC2 ratio | GCST90314683 | 4.96e-05 |
| 11289 | LSP1 levels | GCST90469811 | 4.94e-05 |
| 11290 | Cholesterol to Total Lipids in Large LDL percentage | GCST90497938 | 4.87e-05 |
| 11291 | DAG1/HBEGF ratio | GCST90314376 | 4.87e-05 |
| 11292 | TNFRSF10C levels | GCST90470901 | 4.85e-05 |
| 11293 | Alzheimer's disease (MTAG) | GCST90449060 | 4.84e-05 |
| 11294 | STC2 levels | GCST90470762 | 4.81e-05 |
| 11295 | HippSubfield lh volume GC-ML-DG-head | GCST90002679 | 4.81e-05 |
| 11296 | Thyrotoxicosis | FING00001360 | 4.81e-05 |
| 11297 | CXCL6 levels | GCST90468933 | 4.81e-05 |
| 11298 | Saturated fatty acids levels | GCST90499950 | 4.81e-05 |
| 11299 | Paracetamol of NSAID medication | FING00001145 | 4.77e-05 |
| 11300 | white blood cell count (WBC, mean, inv-norm transformed) | GCST90476454 | 4.76e-05 |
| 11301 | Eosinophil percentage of white cells | GCST004600 | 4.75e-05 |
| 11302 | APOB levels | GCST90092809 | 4.74e-05 |
| 11303 | ITIH4 levels | GCST90469651 | 4.73e-05 |
| 11304 | TPI1 levels | GCST90088659 | 4.72e-05 |
| 11305 | CA3/HMBS ratio | GCST90313584 | 4.71e-05 |
| 11306 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 4.70e-05 |
| 11307 | CD99L2/RARRES2 ratio | GCST90313927 | 4.67e-05 |
| 11308 | Sarcoidosis | FING00001275 | 4.67e-05 |
| 11309 | Docosahexaenoic acid levels | GCST90502254 | 4.67e-05 |
| 11310 | NADK/PXN ratio | GCST90315512 | 4.66e-05 |
| 11311 | Physical activity (standard GWA) | GCST90267292 | 4.65e-05 |
| 11312 | Cholesteryl Esters to Total Lipids in Small LDL percentage | GCST90499595 | 4.64e-05 |
| 11313 | Apple juice liking | GCST90094690 | 4.64e-05 |
| 11314 | C1QA levels | GCST90468485 | 4.63e-05 |
| 11315 | SORT1/ST6GAL1 ratio | GCST90315869 | 4.60e-05 |
| 11316 | Number of diet questionnaires completed | Diet questionnaire performance | UKBB00000536 | 4.58e-05 |
| 11317 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 4.56e-05 |
| 11318 | GRPEL1/MME ratio | GCST90314992 | 4.55e-05 |
| 11319 | Total phospholipid levels in lipoprotein particles | GCST90500124 | 4.54e-05 |
| 11320 | PSRC1 levels | GCST90470365 | 4.51e-05 |
| 11321 | Lymphocyte count | GCST90002388 | 4.49e-05 |
| 11322 | Phospholipid levels in very large VLDL | GCST90093024 | 4.48e-05 |
| 11323 | Triglycerides to Total Lipids in Small VLDL percentage | GCST90499922 | 4.45e-05 |
| 11324 | RNF43 levels | GCST90422482 | 4.43e-05 |
| 11325 | Average total household income before tax | Household | UKBB00000081 | 4.43e-05 |
| 11326 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 4.41e-05 |
| 11327 | Concentration of small LDL particles | GCST90499660 | 4.40e-05 |
| 11328 | Triglycerides to total lipids ratio in IDL | GCST90092842 | 4.40e-05 |
| 11329 | Free cholesterol levels in very large VLDL | GCST90093020 | 4.39e-05 |
| 11330 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500695 | 4.38e-05 |
| 11331 | FCAR/LY96 ratio | GCST90314788 | 4.37e-05 |
| 11332 | Lymphocyte count | GCST004627 | 4.36e-05 |
| 11333 | APBB1IP/NADK ratio | GCST90313298 | 4.34e-05 |
| 11334 | 1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels | GCST90199652 | 4.33e-05 |
| 11335 | Cholesteryl Esters in Small LDL | GCST90499578 | 4.31e-05 |
| 11336 | Basophil percentage of granulocytes | GCST004634 | 4.29e-05 |
| 11337 | Cholesterol in Large VLDL | GCST90498119 | 4.27e-05 |
| 11338 | Visceral adipose tissue normalized | GCST90267358 | 4.25e-05 |
| 11339 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 4.23e-05 |
| 11340 | Average diameter for LDL particles | GCST90092889 | 4.22e-05 |
| 11341 | Omega-6 fatty acids to total fatty acids percentage | GCST90502544 | 4.20e-05 |
| 11342 | IL18 levels | GCST90428411 | 4.20e-05 |
| 11343 | CLEC1B/HBEGF ratio | GCST90314092 | 4.16e-05 |
| 11344 | Monounsaturated fatty acid levels | GCST90502346 | 4.13e-05 |
| 11345 | Total triglycerides levels | GCST90500126 | 4.11e-05 |
| 11346 | Omega-6 fatty acids to total fatty acids percentage | GCST90499210 | 4.10e-05 |
| 11347 | GFER/TRIAP1 ratio | GCST90314921 | 4.10e-05 |
| 11348 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 4.10e-05 |
| 11349 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 4.09e-05 |
| 11350 | Phosphatidylcholine levels | GCST90499240 | 4.09e-05 |
| 11351 | Curry liking | GCST90094750 | 4.09e-05 |
| 11352 | CCN2/ENO2 ratio | GCST90313712 | 4.08e-05 |
| 11353 | NUCB2/RSPO3 ratio | GCST90315575 | 4.08e-05 |
| 11354 | ENPP2 levels | GCST90469115 | 4.05e-05 |
| 11355 | BACH1/DIABLO ratio | GCST90313437 | 4.02e-05 |
| 11356 | Hypercholesterolemia | endocrine/metabolic | UKBB00000332 | 4.02e-05 |
| 11357 | Linoleic acid to total fatty acids percentage | GCST90502017 | 3.99e-05 |
| 11358 | Phospholipids to Total Lipids in Large LDL percentage | GCST90498071 | 3.98e-05 |
| 11359 | Family relationship satisfaction | Mental health | UKBB00000238 | 3.97e-05 |
| 11360 | Omega-6 fatty acid levels | GCST90502103 | 3.97e-05 |
| 11361 | Dermatitis | FING00000401 | 3.97e-05 |
| 11362 | Triglycerides in LDL | GCST90498472 | 3.96e-05 |
| 11363 | Eosinophil count | GCST90002298 | 3.96e-05 |
| 11364 | TSC1 levels | GCST90470972 | 3.94e-05 |
| 11365 | Autoimmune diseases | FING00000131 | 3.93e-05 |
| 11366 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 3.93e-05 |
| 11367 | Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596) | GCST90269693 | 3.93e-05 |
| 11368 | Lymphocyte percentage of white cells | GCST90002389 | 3.92e-05 |
| 11369 | CD40LG levels | GCST90468632 | 3.92e-05 |
| 11370 | Prospective memory result | Prospective memory | UKBB00000713 | 3.91e-05 |
| 11371 | Triglycerides in IDL (UKB data field 23529) | GCST90269626 | 3.90e-05 |
| 11372 | Concentration of medium LDL particles | GCST90092911 | 3.89e-05 |
| 11373 | FADD/PPP1R2 ratio | GCST90314774 | 3.88e-05 |
| 11374 | LAYN/VWC2 ratio | GCST90315293 | 3.88e-05 |
| 11375 | Chronic sinusitis | FING00000298 | 3.87e-05 |
| 11376 | Other symptoms of respiratory system (PheCode 512) | GCST90476039 | 3.87e-05 |
| 11377 | Triglycerides in VLDL | GCST90500304 | 3.86e-05 |
| 11378 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500754 | 3.86e-05 |
| 11379 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90499287 | 3.84e-05 |
| 11380 | Reticulocyte percentage (UKB data field 30240) | GCST90468101 | 3.82e-05 |
| 11381 | Concentration of chylomicrons and extremely large VLDL particles | GCST90093047 | 3.81e-05 |
| 11382 | Own or rent accommodation lived in - Own outright (by you or someone in your household) | Household | UKBB00000623 | 3.81e-05 |
| 11383 | PTPRM/SELE ratio | GCST90315753 | 3.80e-05 |
| 11384 | Dementia, including avohilmo | FING00000395 | 3.79e-05 |
| 11385 | LCN2/PGLYRP1 ratio | GCST90315306 | 3.78e-05 |
| 11386 | Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factors | UKBB00000058 | 3.77e-05 |
| 11387 | Concentration of small HDL particles | GCST90092951 | 3.76e-05 |
| 11388 | IL15/KLRD1 ratio | GCST90315149 | 3.74e-05 |
| 11389 | Biological Sibling: Asthma | GCST90476372 | 3.72e-05 |
| 11390 | Triglycerides in very large HDL | GCST90500482 | 3.72e-05 |
| 11391 | Concentration of medium LDL particles | GCST90498819 | 3.72e-05 |
| 11392 | Free cholesterol in medium HDL | GCST90498563 | 3.71e-05 |
| 11393 | Saturated fatty acids levels | GCST90502659 | 3.69e-05 |
| 11394 | Deaf mutism, not elsewhere classified | FING00000378 | 3.65e-05 |
| 11395 | CRTAP levels | GCST90468872 | 3.64e-05 |
| 11396 | CEACAM6 levels | GCST90468697 | 3.60e-05 |
| 11397 | Concentration of small VLDL particles | GCST90499856 | 3.58e-05 |
| 11398 | Concentration of very large VLDL particles | GCST90093023 | 3.55e-05 |
| 11399 | ERMAP levels | GCST90469147 | 3.54e-05 |
| 11400 | Sum eosinophil basophil counts | GCST004624 | 3.50e-05 |
| 11401 | GOPC/IRAK4 ratio | GCST90314954 | 3.50e-05 |
| 11402 | Triglyceride levels in very large HDL | GCST90132636 | 3.50e-05 |
| 11403 | ITGB1BP2 levels | GCST90012058 | 3.49e-05 |
| 11404 | Cholesteryl Esters in Large HDL | GCST90497753 | 3.49e-05 |
| 11405 | Free cholesterol in large HDL | GCST90497786 | 3.47e-05 |
| 11406 | Phospholipids to total lipids in small VLDL percentage (UKB data field 23599) | GCST90269696 | 3.46e-05 |
| 11407 | Linoleic acid to total fatty acids percentage | GCST90498321 | 3.45e-05 |
| 11408 | Asthma (more control exclusions) | FING00000113 | 3.45e-05 |
| 11409 | RNF41/WWP2 ratio | GCST90315782 | 3.43e-05 |
| 11410 | GZMA levels | GCST90469423 | 3.41e-05 |
| 11411 | Phospholipids to Total Lipids in Small LDL percentage | GCST90499700 | 3.39e-05 |
| 11412 | Hypothyroidism, strict autoimmune | FING00000656 | 3.37e-05 |
| 11413 | Cholesterol levels in large VLDL | GCST90092868 | 3.37e-05 |
| 11414 | PLA2G4A/SDC4 ratio | GCST90315668 | 3.37e-05 |
| 11415 | Omega-3 fatty acid levels | GCST90502425 | 3.36e-05 |
| 11416 | Total fatty acid levels | GCST90502220 | 3.35e-05 |
| 11417 | Total cholesterol minus HDL-C levels | GCST90499129 | 3.34e-05 |
| 11418 | Cholesterol in Small HDL | GCST90499358 | 3.32e-05 |
| 11419 | Eosinophil percentage of granulocytes | GCST004617 | 3.31e-05 |
| 11420 | Anorexia (incl.atypical) | FING00000093 | 3.30e-05 |
| 11421 | CLEC4G/SEMA3F ratio | GCST90314123 | 3.29e-05 |
| 11422 | CD99/RELT ratio | GCST90313930 | 3.29e-05 |
| 11423 | Hypertension | GCST90086092 | 3.28e-05 |
| 11424 | IGSF8 levels | GCST90469540 | 3.28e-05 |
| 11425 | CFHR2 levels | GCST90468726 | 3.27e-05 |
| 11426 | Saturated fatty acids levels | GCST90502186 | 3.27e-05 |
| 11427 | Free cholesterol in small LDL | GCST90499620 | 3.26e-05 |
| 11428 | Triglycerides | GCST002216 | 3.26e-05 |
| 11429 | Comfortable retirement (confirmatory factor analysis Factor 29) | GCST90309363 | 3.25e-05 |
| 11430 | Cholesteryl Esters in Small LDL | GCST90499586 | 3.24e-05 |
| 11431 | Triglyceride levels in VLDL | GCST90093003 | 3.24e-05 |
| 11432 | Frequency of solarium/sunlamp use | Sun exposure | UKBB00000265 | 3.24e-05 |
| 11433 | Glycoprotein acetyls levels (UKB data field 23480) | GCST90269577 | 3.23e-05 |
| 11434 | PM: initial answer - Orange circle| Prospective memory | UKBB00000652 | 3.22e-05 |
| 11435 | Plasma X-24947 levels in chronic kidney disease | GCST90266816 | 3.22e-05 |
| 11436 | Total Lipids in Medium LDL | GCST90498806 | 3.22e-05 |
| 11437 | COL2A1 levels | GCST90468816 | 3.21e-05 |
| 11438 | GP5 levels | GCST90469383 | 3.20e-05 |
| 11439 | Psoriasis vulgaris | FING00001224 | 3.19e-05 |
| 11440 | Cholesteryl Esters to Total Lipids in Large LDL percentage | GCST90497967 | 3.19e-05 |
| 11441 | Graves' disease (PheCode 242.1) | GCST90475644 | 3.19e-05 |
| 11442 | ADH1B levels | GCST90468243 | 3.18e-05 |
| 11443 | Blood cell traits latent factor 18 (platelet) | GCST90559260 | 3.16e-05 |
| 11444 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 3.15e-05 |
| 11445 | Total lipids in small HDL | GCST90499443 | 3.15e-05 |
| 11446 | ERBB4/NELL1 ratio | GCST90314691 | 3.14e-05 |
| 11447 | MSRA/PRDX5 ratio | GCST90315497 | 3.14e-05 |
| 11448 | CRISP2 levels | GCST90468865 | 3.13e-05 |
| 11449 | Broad bean liking | GCST90094711 | 3.12e-05 |
| 11450 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 3.10e-05 |
| 11451 | Alkylphosphatidylcholine (O-34:1) levels | GCST90024925 | 3.08e-05 |
| 11452 | Concentration of VLDL particles | GCST90500246 | 3.08e-05 |
| 11453 | Total fatty acid levels | GCST90502212 | 3.08e-05 |
| 11454 | Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers) | FING00000846 | 3.08e-05 |
| 11455 | ICAM2/SELE ratio | GCST90315120 | 3.07e-05 |
| 11456 | Dementia | FING00000391 | 3.06e-05 |
| 11457 | RETN levels | GCST90012034 | 3.05e-05 |
| 11458 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475458 | 3.05e-05 |
| 11459 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500958 | 3.05e-05 |
| 11460 | CD5 levels | GCST90468641 | 3.04e-05 |
| 11461 | ARSA levels | GCST90468368 | 3.03e-05 |
| 11462 | CFHR5 levels | GCST90468728 | 3.02e-05 |
| 11463 | CLEC4M levels | GCST90468775 | 3.02e-05 |
| 11464 | SDC4/SMAD1 ratio | GCST90315820 | 3.01e-05 |
| 11465 | Cholesterol to Total Lipids in IDL percentage | GCST90497518 | 3.00e-05 |
| 11466 | Concentration of small HDL particles (UKB data field 23572) | GCST90269669 | 3.00e-05 |
| 11467 | Noninfective enteritis and colitis | FING00000881 | 2.99e-05 |
| 11468 | Phospholipid levels in large VLDL | GCST90092876 | 2.99e-05 |
| 11469 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90499302 | 2.99e-05 |
| 11470 | Non-oily fish intake | Diet | UKBB00000525 | 2.98e-05 |
| 11471 | Takes medication for Sleep apnea? | GCST90475258 | 2.98e-05 |
| 11472 | Total lipid levels in large VLDL | GCST90092874 | 2.95e-05 |
| 11473 | TNF/TNFRSF1B ratio | GCST90315942 | 2.95e-05 |
| 11474 | CA14 levels | GCST90468509 | 2.94e-05 |
| 11475 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90093048 | 2.92e-05 |
| 11476 | ACHE levels | GCST90468199 | 2.92e-05 |
| 11477 | CSF1R levels | GCST90468880 | 2.90e-05 |
| 11478 | CEACAM8/MMP9 ratio | GCST90314002 | 2.89e-05 |
| 11479 | CRADD/MAP4K5 ratio | GCST90314240 | 2.89e-05 |
| 11480 | Sicca syndrome [Sjögren] | FING00001304 | 2.87e-05 |
| 11481 | CRTAM levels | GCST90468871 | 2.86e-05 |
| 11482 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90500994 | 2.85e-05 |
| 11483 | LAT/SERPINE1 ratio | GCST90315287 | 2.84e-05 |
| 11484 | Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10) | GCST90042678 | 2.84e-05 |
| 11485 | CRISP3 levels | GCST90468866 | 2.82e-05 |
| 11486 | Triglyceride levels in large HDL | GCST90092854 | 2.82e-05 |
| 11487 | Ankylosing spondylitis | FING00000089 | 2.82e-05 |
| 11488 | Lifespan | GCST90551885 | 2.82e-05 |
| 11489 | Triglyceride to phosphoglyceride ratio | GCST90499992 | 2.79e-05 |
| 11490 | Spicy food liking | GCST90094846 | 2.79e-05 |
| 11491 | Basophil percentage of white cells variance | GCST90565688 | 2.79e-05 |
| 11492 | NUCB2/TRIAP1 ratio | GCST90315577 | 2.77e-05 |
| 11493 | FOXO1/IRAK4 ratio | GCST90314870 | 2.76e-05 |
| 11494 | Platelet distribution width | GCST004616 | 2.74e-05 |
| 11495 | Free Cholesterol to Total Lipids in Small VLDL percentage | GCST90499832 | 2.74e-05 |
| 11496 | Metabolic syndrome | GCST90444487 | 2.74e-05 |
| 11497 | HBEGF/PLXNA4 ratio | GCST90315036 | 2.73e-05 |
| 11498 | Liver condition (ex. cirrhosis) | GCST90475270 | 2.71e-05 |
| 11499 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499740 | 2.71e-05 |
| 11500 | LRG1 levels | GCST90469793 | 2.70e-05 |
| 11501 | CA4/SELE ratio | GCST90313587 | 2.70e-05 |
| 11502 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 2.69e-05 |
| 11503 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 2.69e-05 |
| 11504 | Abnormality of gait (PheCode 350.2) | GCST90475841 | 2.68e-05 |
| 11505 | Triglycerides in large HDL | GCST90497882 | 2.67e-05 |
| 11506 | Cholesterol in small HDL (UKB data field 23575) | GCST90269672 | 2.67e-05 |
| 11507 | BSG levels | GCST90468472 | 2.65e-05 |
| 11508 | APOB levels | GCST90497137 | 2.65e-05 |
| 11509 | CPA2/ITGB7 ratio | GCST90314207 | 2.64e-05 |
| 11510 | DTI TBSS L2 External capsule L | GCST90384509 | 2.63e-05 |
| 11511 | High cholesterol | GCST90468134 | 2.61e-05 |
| 11512 | Cereal type: Muesli (UKB data field 1468_4) | GCST90132972 | 2.60e-05 |
| 11513 | CWC15 levels | GCST90468920 | 2.60e-05 |
| 11514 | IL18BP levels | GCST90469564 | 2.59e-05 |
| 11515 | Average diameter for VLDL particles | GCST90500290 | 2.59e-05 |
| 11516 | Use of hypnotics and sedatives | FING00001411 | 2.59e-05 |
| 11517 | Psoriatic arthritis | GCST90243956 | 2.57e-05 |
| 11518 | Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602) | GCST90269699 | 2.57e-05 |
| 11519 | Monounsaturated fatty acid levels | GCST90502363 | 2.57e-05 |
| 11520 | IL1RAP levels | GCST90469573 | 2.57e-05 |
| 11521 | Total lipids in small VLDL | GCST90499840 | 2.57e-05 |
| 11522 | CD300C/FOLR2 ratio | GCST90313787 | 2.56e-05 |
| 11523 | Monounsaturated fatty acid levels | GCST90502358 | 2.56e-05 |
| 11524 | AMOTL2 levels | GCST90468294 | 2.53e-05 |
| 11525 | Cholesterol, total | GCST000760 | 2.53e-05 |
| 11526 | Cholesteryl Esters to Total Lipids in Medium LDL percentage | GCST90498747 | 2.53e-05 |
| 11527 | FHIT/PARK7 ratio | GCST90314821 | 2.52e-05 |
| 11528 | Omega-6 fatty acid levels | GCST90502502 | 2.50e-05 |
| 11529 | Concentration of large VLDL particles | GCST90092875 | 2.49e-05 |
| 11530 | Operative procedures - Total cholecystectomy NEC | Summary Operations | UKBB00000589 | 2.49e-05 |
| 11531 | WFDC12 levels | GCST90471073 | 2.48e-05 |
| 11532 | CD83 levels | GCST90468652 | 2.47e-05 |
| 11533 | Loneliness (standard GWA) | GCST90267288 | 2.47e-05 |
| 11534 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498101 | 2.45e-05 |
| 11535 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 2.45e-05 |
| 11536 | Free cholesterol levels in large VLDL | GCST90092872 | 2.45e-05 |
| 11537 | Total lipids in very small VLDL | GCST90500813 | 2.44e-05 |
| 11538 | Physical activity (Total log acceleration 8pm-10pm) | GCST90061419 | 2.43e-05 |
| 11539 | Qualifications - O levels/GCSEs or equivalent | Education | UKBB00000731 | 2.43e-05 |
| 11540 | AMBP/RARRES2 ratio | GCST90313256 | 2.42e-05 |
| 11541 | Concentration of small VLDL particles | GCST90092975 | 2.42e-05 |
| 11542 | F11R/GP1BA ratio | GCST90314722 | 2.42e-05 |
| 11543 | F-sweetened coffee drink liking (derived food-liking factor) | GCST90094853 | 2.42e-05 |
| 11544 | Lymphoid neoplasms | GCST90624743 | 2.41e-05 |
| 11545 | Triglycerides to Total Lipids in Medium LDL percentage | GCST90498881 | 2.41e-05 |
| 11546 | GP6/SCARF1 ratio | GCST90314969 | 2.40e-05 |
| 11547 | CC2D1A/CRADD ratio | GCST90313663 | 2.40e-05 |
| 11548 | Total cholesterol levels | GCST90500015 | 2.40e-05 |
| 11549 | LDL cholesterol levels | GCST90498346 | 2.37e-05 |
| 11550 | GGH levels | GCST90469335 | 2.36e-05 |
| 11551 | Docosahexaenoic acid to total fatty acids percentage | GCST90497270 | 2.36e-05 |
| 11552 | Cholesterol levels (UKB data field 30690) | GCST90468066 | 2.35e-05 |
| 11553 | CLEC6A levels | GCST90468777 | 2.34e-05 |
| 11554 | Triglycerides in very small VLDL (UKB data field 23522) | GCST90269619 | 2.33e-05 |
| 11555 | OLR1/OSM ratio | GCST90315583 | 2.33e-05 |
| 11556 | Mean corpuscular volume | GCST90002392 | 2.33e-05 |
| 11557 | Plasma 16a-hydroxy DHEA 3-sulfate levels in chronic kidney disease | GCST90264328 | 2.32e-05 |
| 11558 | Monounsaturated fatty acids levels (UKB data field 23447) | GCST90269544 | 2.31e-05 |
| 11559 | Symptoms concerning nutrition, metabolism, and development (PheCode 1002) | GCST90475556 | 2.31e-05 |
| 11560 | IDP dMRI TBSS L1 Genu of corpus callosum | GCST90004077 | 2.30e-05 |
| 11561 | OSCAR levels | GCST90470131 | 2.30e-05 |
| 11562 | Total esterified cholesterol levels | GCST90500036 | 2.30e-05 |
| 11563 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497790 | 2.29e-05 |
| 11564 | BCAM/NOTCH1 ratio | GCST90313474 | 2.29e-05 |
| 11565 | Cholesterol | Blood biochemistry | UKBB00000134 | 2.28e-05 |
| 11566 | Neutrophil percentage of white cells | GCST004633 | 2.26e-05 |
| 11567 | Cancer of prostate (PheCode 185) | GCST90475591 | 2.26e-05 |
| 11568 | Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5) | GCST90132973 | 2.25e-05 |
| 11569 | Total lipids in large LDL | GCST90498011 | 2.24e-05 |
| 11570 | Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00000777 | 2.23e-05 |
| 11571 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502384 | 2.23e-05 |
| 11572 | Triglycerides to total lipids ratio in large HDL | GCST90092855 | 2.21e-05 |
| 11573 | HPCAL1/LAT ratio | GCST90315072 | 2.20e-05 |
| 11574 | Triglycerides in medium LDL (UKB data field 23543) | GCST90269640 | 2.20e-05 |
| 11575 | Ectopic pregnancy | FING00000487 | 2.19e-05 |
| 11576 | neutrophil (fraction, minimum, inv-norm transformed) | GCST90475541 | 2.19e-05 |
| 11577 | Peripheral or central vertigo (PheCode 386.2) | GCST90475907 | 2.18e-05 |
| 11578 | CXCL16 levels | GCST90468928 | 2.18e-05 |
| 11579 | Triglycerides to total lipids ratio in very large VLDL | GCST90093027 | 2.18e-05 |
| 11580 | Alkylphosphatidylcholine (O-34:1) levels | GCST90025551 | 2.18e-05 |
| 11581 | Free cholesterol to total lipids ratio in medium LDL | GCST90092909 | 2.16e-05 |
| 11582 | Asthma (only as main-diagnosis) (more control exclusions) | FING00000114 | 2.15e-05 |
| 11583 | F-wine liking (derived food-liking factor) | GCST90094872 | 2.15e-05 |
| 11584 | Omega-6 fatty acids levels | GCST90499170 | 2.15e-05 |
| 11585 | Triglycerides to total lipids ratio in medium LDL | GCST90092915 | 2.15e-05 |
| 11586 | Cooked vegetable intake | Diet | UKBB00000147 | 2.14e-05 |
| 11587 | Behenoyl dihydrosphingomyelin (d18:0/22:0) levels | GCST90200059 | 2.13e-05 |
| 11588 | PPP1R2/USP8 ratio | GCST90315723 | 2.12e-05 |
| 11589 | Raw vegetable consumption | GCST90132978 | 2.12e-05 |
| 11590 | Cheese consumption | GCST90133000 | 2.10e-05 |
| 11591 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 2.08e-05 |
| 11592 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 2.08e-05 |
| 11593 | Basal cell carcinoma (MTAG) | GCST90137411 | 2.07e-05 |
| 11594 | CCL2 levels | GCST90468581 | 2.07e-05 |
| 11595 | SORT1/VSIR ratio | GCST90315870 | 2.06e-05 |
| 11596 | Free cholesterol in small VLDL | GCST90499808 | 2.06e-05 |
| 11597 | CD6 levels | GCST90468644 | 2.05e-05 |
| 11598 | F-dairy liking (derived food-liking factor) | GCST90094751 | 2.05e-05 |
| 11599 | Shoulder lesions | FING00001303 | 2.04e-05 |
| 11600 | Free cholesterol levels in very large HDL | GCST90093008 | 2.04e-05 |
| 11601 | Abdominal pain | symptoms | UKBB00000003 | 2.04e-05 |
| 11602 | Total lipids in small HDL (UKB data field 23573) | GCST90269670 | 2.03e-05 |
| 11603 | SLPI levels | GCST90426030 | 2.01e-05 |
| 11604 | EFNA4/TNFRSF9 ratio | GCST90314606 | 2.00e-05 |
| 11605 | Cholesterol in Large LDL | GCST90497919 | 2.00e-05 |
| 11606 | Omega-6 fatty acid levels | GCST90502518 | 1.98e-05 |
| 11607 | Oral glucose tolerance test-0h | GCST90297788 | 1.97e-05 |
| 11608 | Degree of unsaturation | GCST90502737 | 1.97e-05 |
| 11609 | Total free cholesterol levels | GCST90500063 | 1.97e-05 |
| 11610 | Non-albumin protein levels | UKBB00000503 | 1.97e-05 |
| 11611 | Water intake | Diet | UKBB00000906 | 1.95e-05 |
| 11612 | ICAM3/LY9 ratio | GCST90315121 | 1.95e-05 |
| 11613 | Total lipid levels in lipoprotein particles | GCST90092989 | 1.94e-05 |
| 11614 | Crohn disease (strict definition, require KELA, min 2 HDR) | FING00000366 | 1.93e-05 |
| 11615 | Triglyceride levels in medium VLDL | GCST90092926 | 1.93e-05 |
| 11616 | PLB1 levels | GCST90470253 | 1.92e-05 |
| 11617 | PILRB levels | GCST90470237 | 1.91e-05 |
| 11618 | Tinnitus | GCST90448242 | 1.90e-05 |
| 11619 | VLDL cholesterol levels | GCST90092996 | 1.89e-05 |
| 11620 | CX3CL1/EPHB6 ratio | GCST90314324 | 1.89e-05 |
| 11621 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 1.89e-05 |
| 11622 | Neutrophil percentage of granulocytes | GCST004623 | 1.87e-05 |
| 11623 | SPINT2 levels | GCST90470728 | 1.87e-05 |
| 11624 | Triglycerides to total lipids ratio in small LDL | GCST90092967 | 1.86e-05 |
| 11625 | Concentration of very small VLDL particles | GCST90093035 | 1.85e-05 |
| 11626 | ALCAM/ICAM3 ratio | GCST90313237 | 1.85e-05 |
| 11627 | F11R/PLXNA4 ratio | GCST90314724 | 1.85e-05 |
| 11628 | Alanine levels | GCST003666 | 1.84e-05 |
| 11629 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 1.83e-05 |
| 11630 | Omega-6 fatty acids to total fatty acids percentage | GCST90502129 | 1.82e-05 |
| 11631 | Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595) | GCST90269692 | 1.79e-05 |
| 11632 | FCER2/TCL1A ratio | GCST90314790 | 1.79e-05 |
| 11633 | Sleep duration | GCST003839 | 1.79e-05 |
| 11634 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500920 | 1.79e-05 |
| 11635 | Cholesteryl esters to total lipids ratio in large LDL | GCST90092859 | 1.78e-05 |
| 11636 | Total fatty acid levels | GCST90502711 | 1.78e-05 |
| 11637 | Coeliac disease | FING00000312 | 1.77e-05 |
| 11638 | Age when finished full-time education (weighted GWA) | GCST90267281 | 1.75e-05 |
| 11639 | Atopic dermatitis | FING00000125 | 1.75e-05 |
| 11640 | Triglycerides in medium HDL (UKB data field 23571) | GCST90269668 | 1.75e-05 |
| 11641 | CD27/NBL1 ratio | GCST90313774 | 1.74e-05 |
| 11642 | Free cholesterol levels in very small VLDL | GCST90093032 | 1.74e-05 |
| 11643 | Ratio of linoleic acid to total fatty acids | GCST90092881 | 1.70e-05 |
| 11644 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 1.70e-05 |
| 11645 | Citrate levels | GCST90497206 | 1.69e-05 |
| 11646 | Cholesterol to Total Lipids in Small LDL percentage | GCST90499569 | 1.68e-05 |
| 11647 | Free Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498988 | 1.67e-05 |
| 11648 | HBEGF levels | GCST90469433 | 1.67e-05 |
| 11649 | Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00001143 | 1.66e-05 |
| 11650 | Cholesteryl esters to total lipids ratio in medium VLDL | GCST90092919 | 1.66e-05 |
| 11651 | GGT1 levels | GCST90469336 | 1.65e-05 |
| 11652 | SCGB3A1 levels | GCST90470542 | 1.65e-05 |
| 11653 | Mean platelet volume | GCST004599 | 1.65e-05 |
| 11654 | Total lipid levels in very small VLDL | GCST90093034 | 1.63e-05 |
| 11655 | Crohn's disease of small intestine | FING00000369 | 1.62e-05 |
| 11656 | Non-cancer illness code, self-reported - gout | Medical conditions | UKBB00000512 | 1.62e-05 |
| 11657 | CA13/QDPR ratio | GCST90313564 | 1.62e-05 |
| 11658 | DPP6/NELL2 ratio | GCST90314541 | 1.60e-05 |
| 11659 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 1.59e-05 |
| 11660 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500716 | 1.59e-05 |
| 11661 | Concentration of VLDL particles | GCST90093000 | 1.58e-05 |
| 11662 | ROR1/TNFRSF21 ratio | GCST90315787 | 1.57e-05 |
| 11663 | Cholesterol to total lipids ratio in medium LDL | GCST90092905 | 1.56e-05 |
| 11664 | Polyunsaturated fatty acid levels | GCST90502134 | 1.56e-05 |
| 11665 | Free cholesterol to total lipids ratio in large HDL | GCST90092849 | 1.56e-05 |
| 11666 | ENG/TNFRSF10C ratio | GCST90314650 | 1.56e-05 |
| 11667 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90093044 | 1.55e-05 |
| 11668 | CALCOCO1/PFKFB2 ratio | GCST90313608 | 1.55e-05 |
| 11669 | Cholesterol to total lipids ratio in large HDL | GCST90092845 | 1.55e-05 |
| 11670 | MMP9 levels | GCST90469923 | 1.54e-05 |
| 11671 | CD27 levels | GCST90468615 | 1.53e-05 |
| 11672 | Waking up during the night and not easily going back to sleep | GCST90476386 | 1.53e-05 |
| 11673 | Melanomas of skin (PheCode 172.11) | GCST90475578 | 1.53e-05 |
| 11674 | Triglycerides in HDL (UKB data field 23410) | GCST90269507 | 1.53e-05 |
| 11675 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499369 | 1.52e-05 |
| 11676 | Triglycerides x depression interaction (2df test) | GCST90570679 | 1.51e-05 |
| 11677 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90093040 | 1.50e-05 |
| 11678 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501015 | 1.49e-05 |
| 11679 | PLA2G15 levels | GCST90470245 | 1.48e-05 |
| 11680 | Aspartate aminotransferase levels | GCST90018724 | 1.48e-05 |
| 11681 | Whiskey liking | GCST90094873 | 1.48e-05 |
| 11682 | Omega-6 fatty acids levels | GCST90499177 | 1.47e-05 |
| 11683 | PSRC1/SORT1 ratio | GCST90315742 | 1.47e-05 |
| 11684 | Triglycerides in LDL (UKB data field 23409) | GCST90269506 | 1.47e-05 |
| 11685 | Free cholesterol to total lipids ratio in IDL | GCST90092836 | 1.47e-05 |
| 11686 | Principal component-derived dietary pattern 16 | GCST90133021 | 1.47e-05 |
| 11687 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90093042 | 1.46e-05 |
| 11688 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499111 | 1.46e-05 |
| 11689 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500983 | 1.45e-05 |
| 11690 | Percentage of invited food questionnaires completed | GCST90012790 | 1.45e-05 |
| 11691 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 1.43e-05 |
| 11692 | Linoleic acid levels | GCST90502294 | 1.43e-05 |
| 11693 | Varicose veins of lower extremity, symptomtic (PheCode 454.11) | GCST90476014 | 1.43e-05 |
| 11694 | Average diameter for HDL particles | GCST90132702 | 1.42e-05 |
| 11695 | Cholesterol to total lipids in large HDL percentage (UKB data field 23635) | GCST90269732 | 1.42e-05 |
| 11696 | TNFRSF6B levels | GCST90470914 | 1.42e-05 |
| 11697 | Saturated fatty acids to total fatty acids percentage | GCST90499966 | 1.42e-05 |
| 11698 | Birth year infant mortality rates | GCST90095047 | 1.41e-05 |
| 11699 | METAP2/USP8 ratio | GCST90315434 | 1.41e-05 |
| 11700 | Omega-6 fatty acid levels | GCST90502514 | 1.41e-05 |
| 11701 | SERPINB1/SERPINB9 ratio | GCST90315827 | 1.41e-05 |
| 11702 | CD80 levels | GCST90468650 | 1.41e-05 |
| 11703 | SERPIND1 levels | GCST90470595 | 1.40e-05 |
| 11704 | Tyrosine levels (UKB data field 23469) | GCST90269566 | 1.40e-05 |
| 11705 | Pain (limb, back, neck, head abdominally) | FING00001135 | 1.40e-05 |
| 11706 | Triglycerides in small LDL | GCST90499712 | 1.39e-05 |
| 11707 | LBR/PSRC1 ratio | GCST90315300 | 1.39e-05 |
| 11708 | GCNT1 levels | GCST90469319 | 1.38e-05 |
| 11709 | EREG/HBEGF ratio | GCST90314702 | 1.38e-05 |
| 11710 | sodium (minimum, inv-norm transformed) | GCST90476397 | 1.38e-05 |
| 11711 | CES2 levels | GCST90468719 | 1.37e-05 |
| 11712 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 1.36e-05 |
| 11713 | X-24544 levels | GCST90200636 | 1.36e-05 |
| 11714 | Triglycerides in large LDL (UKB data field 23536) | GCST90269633 | 1.35e-05 |
| 11715 | Polyunsaturated fatty acid levels | GCST90502606 | 1.34e-05 |
| 11716 | DTI autoptx L2 cgc r tract | GCST90385171 | 1.33e-05 |
| 11717 | Frontotemporal dementia | FING00000560 | 1.33e-05 |
| 11718 | Allergic contact dermatitis | FING00000068 | 1.33e-05 |
| 11719 | Total lipids in small LDL | GCST90499652 | 1.33e-05 |
| 11720 | Free Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500791 | 1.32e-05 |
| 11721 | IGLC2 levels | GCST90469536 | 1.32e-05 |
| 11722 | Alanine levels | GCST90092806 | 1.32e-05 |
| 11723 | INSL5 levels | GCST90469622 | 1.31e-05 |
| 11724 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 1.30e-05 |
| 11725 | ADGRE5/SEMA7A ratio | GCST90313183 | 1.30e-05 |
| 11726 | aparc-a2009s rh thickness G+S-cingul-Ant | GCST90003682 | 1.29e-05 |
| 11727 | Degree of unsaturation | GCST90500162 | 1.28e-05 |
| 11728 | NINJ1 levels | GCST90470049 | 1.28e-05 |
| 11729 | CANT1 levels | GCST90468536 | 1.27e-05 |
| 11730 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 1.26e-05 |
| 11731 | CD300E/EFNA4 ratio | GCST90313797 | 1.26e-05 |
| 11732 | Eosinophil count | GCST90025987 | 1.25e-05 |
| 11733 | Gout, strict definition | FING00000588 | 1.25e-05 |
| 11734 | Free cholesterol levels in VLDL | GCST90092998 | 1.24e-05 |
| 11735 | Frequency of unenthusiasm / disinterest in last 2 weeks | Mental health | UKBB00000270 | 1.23e-05 |
| 11736 | LAYN/ULBP2 ratio | GCST90315292 | 1.23e-05 |
| 11737 | Mean corpuscular hemoglobin | GCST90002323 | 1.21e-05 |
| 11738 | Triglyceride levels in very large HDL | GCST90093014 | 1.21e-05 |
| 11739 | DTI TBSS MD Anterior limb of internal capsule R | GCST90384588 | 1.21e-05 |
| 11740 | Taking other prescription medications | Medication | UKBB00000813 | 1.21e-05 |
| 11741 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 1.19e-05 |
| 11742 | ITIH3 levels | GCST90469650 | 1.19e-05 |
| 11743 | Free cholesterol to total lipids ratio in very large VLDL | GCST90093021 | 1.19e-05 |
| 11744 | PRSS8 levels | GCST90470345 | 1.19e-05 |
| 11745 | N6-methyllysine levels in chronic kidney disease | GCST90257530 | 1.19e-05 |
| 11746 | FASLG levels | GCST90469191 | 1.18e-05 |
| 11747 | LEP levels | GCST90469757 | 1.17e-05 |
| 11748 | FETUB levels | GCST90469215 | 1.16e-05 |
| 11749 | NELL2/SEZ6L ratio | GCST90315536 | 1.16e-05 |
| 11750 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 1.15e-05 |
| 11751 | Total fatty acid levels | GCST90500061 | 1.15e-05 |
| 11752 | F9/RARRES2 ratio | GCST90314749 | 1.14e-05 |
| 11753 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 1.14e-05 |
| 11754 | TNFRSF1B levels | GCST90470911 | 1.12e-05 |
| 11755 | Linoleic acid to total fatty acids percentage | GCST90502336 | 1.11e-05 |
| 11756 | MAP4K5/TBCB ratio | GCST90315384 | 1.11e-05 |
| 11757 | Cholesteryl esters in small HDL (UKB data field 23576) | GCST90269673 | 1.11e-05 |
| 11758 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500866 | 1.11e-05 |
| 11759 | Acute alcohol intoxication, ICD10 | FING00000015 | 1.11e-05 |
| 11760 | CREG1 levels | GCST90468857 | 1.11e-05 |
| 11761 | T1 FreeSurfer aseg Left-Caudate | GCST90384144 | 1.10e-05 |
| 11762 | F-meat liking (derived food-liking factor) | GCST90094799 | 1.10e-05 |
| 11763 | Feeling lonely | GCST006942 | 1.10e-05 |
| 11764 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501050 | 1.09e-05 |
| 11765 | Obesity due to excess calories | FING00000896 | 1.09e-05 |
| 11766 | KLK11 levels | GCST90012012 | 1.09e-05 |
| 11767 | Plasma pregnenetriol disulfate* levels in chronic kidney disease | GCST90265864 | 1.08e-05 |
| 11768 | Lifespan | GCST90551884 | 1.07e-05 |
| 11769 | LILRB1 levels | GCST90469776 | 1.06e-05 |
| 11770 | KLK14 levels | GCST90469700 | 1.05e-05 |
| 11771 | LGALS9 levels | GCST90469765 | 1.05e-05 |
| 11772 | SDC4/SELP ratio | GCST90315817 | 1.05e-05 |
| 11773 | ASS1 levels | GCST90468380 | 1.04e-05 |
| 11774 | CLEC4G/LGALS4 ratio | GCST90314120 | 1.04e-05 |
| 11775 | Phospholipids to total lipids ratio in medium LDL | GCST90092913 | 1.03e-05 |
| 11776 | Linoleic acid levels | GCST90502004 | 1.02e-05 |
| 11777 | Eosinophil count | GCST90018733 | 1.02e-05 |
| 11778 | CTSB levels | GCST90468908 | 1.01e-05 |
| 11779 | IL5RA levels | GCST90469600 | 1.01e-05 |
| 11780 | Recent feelings of depression | Depression | UKBB00000737 | 1.00e-05 |
| 11781 | Cholesterol to total lipids in large VLDL percentage (UKB data field 23590) | GCST90269687 | 1.00e-05 |
| 11782 | Triglycerides to Total Lipids in Small HDL percentage | GCST90499530 | 9.98e-06 |
| 11783 | Linoleic acid levels | GCST90502310 | 9.95e-06 |
| 11784 | Attendance/disability/mobility allowance - None of the above | Other sociodemographic factors | UKBB00000059 | 9.93e-06 |
| 11785 | Total lipid levels in small VLDL | GCST90092974 | 9.88e-06 |
| 11786 | Pollinosis | GCST90018683 | 9.87e-06 |
| 11787 | Reason for reducing amount of alcohol drunk - Health precaution | Alcohol | UKBB00000734 | 9.85e-06 |
| 11788 | Omega-3 fatty acids to total fatty acids percentage | GCST90499155 | 9.82e-06 |
| 11789 | CLEC1A/TNFRSF1A ratio | GCST90314085 | 9.78e-06 |
| 11790 | CKAP4/TNFRSF4 ratio | GCST90314076 | 9.74e-06 |
| 11791 | Age when finished full-time education (standard GWA) | GCST90267280 | 9.71e-06 |
| 11792 | SBSN levels | GCST90470531 | 9.70e-06 |
| 11793 | Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598) | GCST90269695 | 9.63e-06 |
| 11794 | SPINT1/SUSD2 ratio | GCST90315878 | 9.61e-06 |
| 11795 | CA9 levels | GCST90468518 | 9.55e-06 |
| 11796 | Frailty (Factor 2 - Unhealthy Lifestyle) | GCST90624048 | 9.53e-06 |
| 11797 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 9.52e-06 |
| 11798 | Triglycerides to total lipids ratio in medium HDL | GCST90092903 | 9.47e-06 |
| 11799 | CALCOCO1/INPPL1 ratio | GCST90313603 | 9.42e-06 |
| 11800 | IFI30 levels | GCST90469509 | 9.38e-06 |
| 11801 | LILRB2 levels | GCST90469777 | 9.34e-06 |
| 11802 | TNFRSF10B levels | GCST90470900 | 9.30e-06 |
| 11803 | Average diameter for HDL particles | GCST90497446 | 9.29e-06 |
| 11804 | Cholesterol levels in very small VLDL | GCST90500700 | 9.27e-06 |
| 11805 | MMP9/OLR1 ratio | GCST90315467 | 9.24e-06 |
| 11806 | Cholesterol esters in very small VLDL | GCST90500740 | 9.20e-06 |
| 11807 | mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed) | GCST90475462 | 9.19e-06 |
| 11808 | CXCL5/SDC4 ratio | GCST90314353 | 9.17e-06 |
| 11809 | TIA1/USP8 ratio | GCST90315920 | 9.17e-06 |
| 11810 | CASP3/SNAP23 ratio | GCST90313644 | 9.14e-06 |
| 11811 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 9.13e-06 |
| 11812 | Phospholipid levels in VLDL | GCST90093001 | 9.10e-06 |
| 11813 | T1 FreeSurfer BA lh BA3a exvivo thickness | GCST90385521 | 9.10e-06 |
| 11814 | Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000641 | 9.00e-06 |
| 11815 | Patient classification on admission (recoded) - Inpatient | Summary Administration | UKBB00000637 | 8.96e-06 |
| 11816 | F2R/TNFRSF14 ratio | GCST90314739 | 8.96e-06 |
| 11817 | FHIT/GLOD4 ratio | GCST90314817 | 8.93e-06 |
| 11818 | HippSubfield lh volume CA4-head | GCST90002682 | 8.92e-06 |
| 11819 | Triglycerides to Total Lipids in IDL percentage | GCST90497682 | 8.92e-06 |
| 11820 | Principal component-derived dietary pattern 36 | GCST90133041 | 8.89e-06 |
| 11821 | Total free cholesterol levels | GCST90092988 | 8.87e-06 |
| 11822 | Linoleic acid levels | GCST90092880 | 8.84e-06 |
| 11823 | CD6/EZR ratio | GCST90313890 | 8.82e-06 |
| 11824 | Phospholipid levels in very large HDL | GCST90132642 | 8.80e-06 |
| 11825 | Lymphocyte percentage of white cells | GCST004632 | 8.74e-06 |
| 11826 | SMNDC1 levels | GCST90470681 | 8.71e-06 |
| 11827 | Provencibacterium abundance in stool | GCST90032528 | 8.70e-06 |
| 11828 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 8.69e-06 |
| 11829 | Prescriptions - antispasmodic | UKBB00000666 | 8.56e-06 |
| 11830 | CDKN1A/HBEGF ratio | GCST90313972 | 8.55e-06 |
| 11831 | PCSK7 levels | GCST90470176 | 8.52e-06 |
| 11832 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 8.46e-06 |
| 11833 | 1-ribosyl-imidazoleacetate levels | GCST90199815 | 8.35e-06 |
| 11834 | KLK8/NECTIN4 ratio | GCST90315258 | 8.32e-06 |
| 11835 | Any mental disorder | FING00000100 | 8.31e-06 |
| 11836 | THPO levels | GCST90470857 | 8.31e-06 |
| 11837 | EBAG9/TGFB1 ratio | GCST90314570 | 8.22e-06 |
| 11838 | KLK8 levels | GCST90469707 | 8.20e-06 |
| 11839 | Propionylglycine levels | GCST90199705 | 8.15e-06 |
| 11840 | Beef/steak liking | GCST90094700 | 8.12e-06 |
| 11841 | ITGB7 levels | GCST90469647 | 8.09e-06 |
| 11842 | LAMP2 levels | GCST90469734 | 8.07e-06 |
| 11843 | Cholesterol levels in small HDL | GCST90092944 | 8.06e-06 |
| 11844 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498293 | 8.05e-06 |
| 11845 | TNFSF10 levels | GCST90470917 | 8.03e-06 |
| 11846 | Linoleic acid levels | GCST90502306 | 7.99e-06 |
| 11847 | MARCO levels | GCST90469861 | 7.99e-06 |
| 11848 | RASSF2 levels | GCST90470431 | 7.96e-06 |
| 11849 | Concentration of small HDL particles | GCST90499461 | 7.91e-06 |
| 11850 | BBQ/grilled meat liking | GCST90094698 | 7.90e-06 |
| 11851 | Linoleic acid levels | GCST90498306 | 7.86e-06 |
| 11852 | Irritable bowel syndrome | GCST90243958 | 7.79e-06 |
| 11853 | Cholesterol to total lipids in medium LDL percentage (UKB data field 23620) | GCST90269717 | 7.78e-06 |
| 11854 | CST3/IL18BP ratio | GCST90314294 | 7.69e-06 |
| 11855 | Dermatophytosis (PheCode 110.1) | GCST90475561 | 7.66e-06 |
| 11856 | LGALS4 levels | GCST90469762 | 7.63e-06 |
| 11857 | ST6GAL1 levels | GCST90470753 | 7.56e-06 |
| 11858 | High light scatter reticulocyte percentage of red cells | GCST004612 | 7.49e-06 |
| 11859 | Other degenerative diseases of the nervous system | FING00000994 | 7.44e-06 |
| 11860 | Other soft tissue disorders, not elsewhere classified | FING00001099 | 7.41e-06 |
| 11861 | Frequency of walking for pleasure in last 4 weeks | Physical activity | UKBB00000271 | 7.41e-06 |
| 11862 | CCL23 levels | GCST90468575 | 7.38e-06 |
| 11863 | Cholesterol to Total Lipids in Medium LDL percentage | GCST90498714 | 7.37e-06 |
| 11864 | Mean corpuscular volume | GCST90002335 | 7.24e-06 |
| 11865 | KLRB1 levels | GCST90469709 | 7.23e-06 |
| 11866 | FGF21/LEP ratio | GCST90314810 | 7.22e-06 |
| 11867 | Own or rent accommodation lived in - Rent - from local authority, local council, housing association | Household | UKBB00000624 | 7.15e-06 |
| 11868 | DTI TBSS L1 Anterior corona radiata L | GCST90384451 | 7.07e-06 |
| 11869 | Hypercalcemia (PheCode 275.6) | GCST90475748 | 7.05e-06 |
| 11870 | Gestational age at birth (maternal effect) | GCST90268419 | 7.05e-06 |
| 11871 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 7.04e-06 |
| 11872 | Phospholipids in small VLDL | GCST90499881 | 6.95e-06 |
| 11873 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 6.94e-06 |
| 11874 | Monounsaturated fatty acid levels | GCST90502038 | 6.92e-06 |
| 11875 | DAPP1/PTPN6 ratio | GCST90314397 | 6.90e-06 |
| 11876 | Total lipid levels in VLDL | GCST90092999 | 6.88e-06 |
| 11877 | PDCD1/TNFRSF4 ratio | GCST90315609 | 6.88e-06 |
| 11878 | C19ORF12 levels | GCST90468483 | 6.86e-06 |
| 11879 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497868 | 6.82e-06 |
| 11880 | Phospholipids to Total Lipids in Medium LDL percentage | GCST90498852 | 6.76e-06 |
| 11881 | Cholesteryl Esters in Large LDL | GCST90497949 | 6.65e-06 |
| 11882 | Bifidobacterium kashiwanohense abundance in stool | GCST90032226 | 6.63e-06 |
| 11883 | CD7 levels | GCST90468649 | 6.61e-06 |
| 11884 | CEP43/USP8 ratio | GCST90314022 | 6.57e-06 |
| 11885 | Concentration of very small VLDL particles | GCST90500826 | 6.52e-06 |
| 11886 | T1 FreeSurfer aseg Right-Caudate | GCST90384162 | 6.52e-06 |
| 11887 | Tyrosine levels | GCST90092993 | 6.45e-06 |
| 11888 | Physical activity (Total log acceleration 6pm-8pm) | GCST90061418 | 6.43e-06 |
| 11889 | Monounsaturated fatty acid levels | GCST90502030 | 6.41e-06 |
| 11890 | CD22/TCL1A ratio | GCST90313760 | 6.40e-06 |
| 11891 | ERBB2/GUSB ratio | GCST90314687 | 6.37e-06 |
| 11892 | RRM2 levels | GCST90470501 | 6.36e-06 |
| 11893 | Omega-6 fatty acids to total fatty acids percentage | GCST90502529 | 6.33e-06 |
| 11894 | Other and unspecified tonsillitis | FING00000954 | 6.31e-06 |
| 11895 | VCAM1 levels | GCST90471031 | 6.23e-06 |
| 11896 | CD300E/CD59 ratio | GCST90313794 | 6.21e-06 |
| 11897 | Principal component-derived dietary pattern 24 | GCST90133029 | 6.17e-06 |
| 11898 | Nontoxic goitre/thyroid nodule | FING00000887 | 6.15e-06 |
| 11899 | SERPINC1 levels | GCST90470594 | 6.15e-06 |
| 11900 | DCXR/SCLY ratio | GCST90314440 | 6.14e-06 |
| 11901 | Hypothyroidism | GCST90204167 | 6.14e-06 |
| 11902 | CLEC4G/KDR ratio | GCST90314118 | 6.12e-06 |
| 11903 | Total lipids in large HDL | GCST90497818 | 6.08e-06 |
| 11904 | Dermatophytosis / Dermatomycosis (PheCode 110) | GCST90475560 | 6.04e-06 |
| 11905 | DTI TBSS MD Anterior limb of internal capsule L | GCST90384589 | 6.01e-06 |
| 11906 | MS-disease / Multiple Sclerosis | FING00000839 | 5.98e-06 |
| 11907 | Total lipid levels in lipoprotein particles | GCST90500085 | 5.98e-06 |
| 11908 | Concentration of large HDL particles | GCST90497836 | 5.96e-06 |
| 11909 | LPO levels | GCST90469789 | 5.95e-06 |
| 11910 | HPCAL1/SERPINB9 ratio | GCST90315079 | 5.94e-06 |
| 11911 | Rubneribacter sp002159915 abundance in stool | GCST90032541 | 5.92e-06 |
| 11912 | CSF1 levels | GCST90468881 | 5.88e-06 |
| 11913 | Cholesteryl Esters in Small HDL | GCST90499386 | 5.86e-06 |
| 11914 | PDCD1 levels | GCST90470181 | 5.83e-06 |
| 11915 | CDC37/SNX9 ratio | GCST90313936 | 5.70e-06 |
| 11916 | Other Crohn's disease | FING00000992 | 5.68e-06 |
| 11917 | Total fatty acid levels | GCST90502722 | 5.66e-06 |
| 11918 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 5.66e-06 |
| 11919 | F11R/TMSB10 ratio | GCST90314729 | 5.55e-06 |
| 11920 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 5.54e-06 |
| 11921 | N-delta-acetylornithine levels | GCST90200691 | 5.51e-06 |
| 11922 | CPM/LAMP2 ratio | GCST90314215 | 5.47e-06 |
| 11923 | GP1BA/SIAE ratio | GCST90314959 | 5.37e-06 |
| 11924 | Ratio of saturated fatty acids to total fatty acids | GCST90092981 | 5.33e-06 |
| 11925 | Seborrhoeic dermatitis | FING00001282 | 5.31e-06 |
| 11926 | F-dessert liking (derived food-liking factor) | GCST90094754 | 5.29e-06 |
| 11927 | Total fatty acid levels | GCST90502726 | 5.20e-06 |
| 11928 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 5.17e-06 |
| 11929 | CALCOCO1/METAP2 ratio | GCST90313606 | 5.13e-06 |
| 11930 | Omega-3 fatty acid levels | GCST90502422 | 5.09e-06 |
| 11931 | Mean reticulocyte volume | GCST90025975 | 5.08e-06 |
| 11932 | Glycated haemoglobin HbA1c levels (UKB data field 30750) | GCST90468072 | 5.02e-06 |
| 11933 | Types of physical activity in last 4 weeks - Other exercises (eg: swimming, cycling, keep fit, bowling) | Physical activity | UKBB00000873 | 5.01e-06 |
| 11934 | Triglycerides to total lipids ratio in very small VLDL | GCST90093039 | 5.01e-06 |
| 11935 | Croissant liking | GCST90094748 | 5.00e-06 |
| 11936 | Triglyceride levels in small HDL | GCST90092954 | 4.99e-06 |
| 11937 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 4.97e-06 |
| 11938 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 4.94e-06 |
| 11939 | Cholesteryl ester levels in small HDL | GCST90092946 | 4.91e-06 |
| 11940 | Lichen simplex chronicus and prurigo | FING00000725 | 4.91e-06 |
| 11941 | Linoleic acid to total fatty acids percentage (UKB data field 23456) | GCST90269553 | 4.90e-06 |
| 11942 | Total Lipids in LDL | GCST90498396 | 4.89e-06 |
| 11943 | Total fatty acid levels | GCST90500053 | 4.83e-06 |
| 11944 | CRTAM/ICAM3 ratio | GCST90314276 | 4.82e-06 |
| 11945 | Colon cancer/rectal cancer | GCST90475170 | 4.81e-06 |
| 11946 | Type1 diabetes, definitions combined, early onset | FING00001384 | 4.80e-06 |
| 11947 | ALDH1A1/PKLR ratio | GCST90313245 | 4.77e-06 |
| 11948 | Cholelithiasis and cholecystitis | digestive | UKBB00000133 | 4.75e-06 |
| 11949 | CD40/ITGB5 ratio | GCST90313816 | 4.63e-06 |
| 11950 | GALNT10/SEMA7A ratio | GCST90314915 | 4.61e-06 |
| 11951 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 4.61e-06 |
| 11952 | SLAMF1 levels | GCST90470649 | 4.58e-06 |
| 11953 | Reason for glasses/contact lenses - For 'astigmatism' | Eyesight | UKBB00000733 | 4.55e-06 |
| 11954 | CD84/SDC4 ratio | GCST90313916 | 4.53e-06 |
| 11955 | ACE2 levels | GCST90468197 | 4.51e-06 |
| 11956 | TNFSF11 levels | GCST90274844 | 4.51e-06 |
| 11957 | BLNK levels | GCST90468448 | 4.48e-06 |
| 11958 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 4.46e-06 |
| 11959 | IFNAR1 levels | GCST90469512 | 4.41e-06 |
| 11960 | TCN2 levels | GCST90470820 | 4.38e-06 |
| 11961 | Cholesterol to total lipids ratio in large LDL | GCST90092857 | 4.37e-06 |
| 11962 | PRCP levels | GCST90470314 | 4.37e-06 |
| 11963 | CA13/TYMP ratio | GCST90313568 | 4.36e-06 |
| 11964 | Basophil count | GCST90002292 | 4.31e-06 |
| 11965 | SDC4/SERPINE1 ratio | GCST90315819 | 4.30e-06 |
| 11966 | GZMB levels | GCST90469424 | 4.30e-06 |
| 11967 | Glycated haemoglobin (HbA1c) | Blood biochemistry | UKBB00000289 | 4.28e-06 |
| 11968 | Saturated fatty acids levels | GCST90502670 | 4.26e-06 |
| 11969 | CD5/IL16 ratio | GCST90313861 | 4.22e-06 |
| 11970 | Phospholipids in small HDL (UKB data field 23574) | GCST90269671 | 4.21e-06 |
| 11971 | Red wine consumption (glasses per month) (UKB data field 1578, 4419) | GCST90132987 | 4.16e-06 |
| 11972 | Rash and other nonspecific skin eruption (PheCode 687.1) | GCST90476167 | 4.14e-06 |
| 11973 | Omega-6 fatty acids to total fatty acids percentage | GCST90502528 | 4.13e-06 |
| 11974 | Takes medication for migraine headaches? | GCST90475547 | 4.09e-06 |
| 11975 | Monounsaturated fatty acid levels | GCST90502362 | 4.07e-06 |
| 11976 | EREG/GYS1 ratio | GCST90314701 | 4.06e-06 |
| 11977 | ITGAL levels | GCST90469637 | 4.05e-06 |
| 11978 | TGFB1 levels | GCST90274818 | 4.05e-06 |
| 11979 | HBEGF/PDGFA ratio | GCST90315033 | 4.04e-06 |
| 11980 | Saturated fatty acids levels | GCST90502658 | 4.04e-06 |
| 11981 | TFRC levels | GCST90451684 | 3.99e-06 |
| 11982 | CFI levels | GCST90468730 | 3.98e-06 |
| 11983 | Omega-3 fatty acid levels | GCST90502061 | 3.98e-06 |
| 11984 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 3.91e-06 |
| 11985 | CD86 levels | GCST90468654 | 3.88e-06 |
| 11986 | Basophil count variance | GCST90565682 | 3.86e-06 |
| 11987 | CD22 levels | GCST90468610 | 3.80e-06 |
| 11988 | Poultry consumption | GCST90132996 | 3.80e-06 |
| 11989 | Basophil count | GCST90002379 | 3.77e-06 |
| 11990 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 3.76e-06 |
| 11991 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500506 | 3.76e-06 |
| 11992 | REG1A/TFF3 ratio | GCST90315764 | 3.72e-06 |
| 11993 | BAG6/BMP6 ratio | GCST90313450 | 3.63e-06 |
| 11994 | FADD/PLIN3 ratio | GCST90314772 | 3.58e-06 |
| 11995 | HIP1R levels | GCST90469453 | 3.52e-06 |
| 11996 | PLAUR levels | GCST90470251 | 3.47e-06 |
| 11997 | CD300A levels | GCST90468619 | 3.45e-06 |
| 11998 | Erythematous conditions (PheCode 695) | GCST90476177 | 3.37e-06 |
| 11999 | Coffee intake (standard GWA) | GCST90267274 | 3.33e-06 |
| 12000 | Cholesterol to total lipids in small LDL percentage (UKB data field 23625) | GCST90269722 | 3.32e-06 |